Cargando…
Neural crest‐derived mesenchymal progenitor cells enhance cranial allograft integration
Replacement of lost cranial bone (partly mesodermal and partly neural crest‐derived) is challenging and includes the use of nonviable allografts. To revitalize allografts, bone marrow‐derived mesenchymal stromal cells (mesoderm‐derived BM‐MSCs) have been used with limited success. We hypothesize tha...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046069/ https://www.ncbi.nlm.nih.gov/pubmed/33512772 http://dx.doi.org/10.1002/sctm.20-0364 |
_version_ | 1783678777135464448 |
---|---|
author | Glaeser, Juliane D. Behrens, Phillip Stefanovic, Tina Salehi, Khosrowdad Papalamprou, Angela Tawackoli, Wafa Metzger, Melodie F. Eberlein, Samuel Nelson, Trevor Arabi, Yasaman Kim, Kevin Baloh, Robert H. Ben‐David, Shiran Cohn‐Schwartz, Doron Ryu, Robert Bae, Hyun W. Gazit, Zulma Sheyn, Dmitriy |
author_facet | Glaeser, Juliane D. Behrens, Phillip Stefanovic, Tina Salehi, Khosrowdad Papalamprou, Angela Tawackoli, Wafa Metzger, Melodie F. Eberlein, Samuel Nelson, Trevor Arabi, Yasaman Kim, Kevin Baloh, Robert H. Ben‐David, Shiran Cohn‐Schwartz, Doron Ryu, Robert Bae, Hyun W. Gazit, Zulma Sheyn, Dmitriy |
author_sort | Glaeser, Juliane D. |
collection | PubMed |
description | Replacement of lost cranial bone (partly mesodermal and partly neural crest‐derived) is challenging and includes the use of nonviable allografts. To revitalize allografts, bone marrow‐derived mesenchymal stromal cells (mesoderm‐derived BM‐MSCs) have been used with limited success. We hypothesize that coating of allografts with induced neural crest cell‐mesenchymal progenitor cells (iNCC‐MPCs) improves implant‐to‐bone integration in mouse cranial defects. Human induced pluripotent stem cells were reprogramed from dermal fibroblasts, differentiated to iNCCs and then to iNCC‐MPCs. BM‐MSCs were used as reference. Cells were labeled with luciferase (Luc2) and characterized for MSC consensus markers expression, differentiation, and risk of cellular transformation. A calvarial defect was created in non‐obese diabetic/severe combined immunodeficiency (NOD/SCID) mice and allografts were implanted, with or without cell coating. Bioluminescence imaging (BLI), microcomputed tomography (μCT), histology, immunofluorescence, and biomechanical tests were performed. Characterization of iNCC‐MPC‐Luc2 vs BM‐MSC‐Luc2 showed no difference in MSC markers expression and differentiation in vitro. In vivo, BLI indicated survival of both cell types for at least 8 weeks. At week 8, μCT analysis showed enhanced structural parameters in the iNCC‐MPC‐Luc2 group and increased bone volume in the BM‐MSC‐Luc2 group compared to controls. Histology demonstrated improved integration of iNCC‐MPC‐Luc2 allografts compared to BM‐MSC‐Luc2 group and controls. Human osteocalcin and collagen type 1 were detected at the allograft‐host interphase in cell‐seeded groups. The iNCC‐MPC‐Luc2 group also demonstrated improved biomechanical properties compared to BM‐MSC‐Luc2 implants and cell‐free controls. Our results show an improved integration of iNCC‐MPC‐Luc2‐coated allografts compared to BM‐MSC‐Luc2 and controls, suggesting the use of iNCC‐MPCs as potential cell source for cranial bone repair. |
format | Online Article Text |
id | pubmed-8046069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80460692021-04-16 Neural crest‐derived mesenchymal progenitor cells enhance cranial allograft integration Glaeser, Juliane D. Behrens, Phillip Stefanovic, Tina Salehi, Khosrowdad Papalamprou, Angela Tawackoli, Wafa Metzger, Melodie F. Eberlein, Samuel Nelson, Trevor Arabi, Yasaman Kim, Kevin Baloh, Robert H. Ben‐David, Shiran Cohn‐Schwartz, Doron Ryu, Robert Bae, Hyun W. Gazit, Zulma Sheyn, Dmitriy Stem Cells Transl Med Tissue‐specific Progenitor and Stem Cells Replacement of lost cranial bone (partly mesodermal and partly neural crest‐derived) is challenging and includes the use of nonviable allografts. To revitalize allografts, bone marrow‐derived mesenchymal stromal cells (mesoderm‐derived BM‐MSCs) have been used with limited success. We hypothesize that coating of allografts with induced neural crest cell‐mesenchymal progenitor cells (iNCC‐MPCs) improves implant‐to‐bone integration in mouse cranial defects. Human induced pluripotent stem cells were reprogramed from dermal fibroblasts, differentiated to iNCCs and then to iNCC‐MPCs. BM‐MSCs were used as reference. Cells were labeled with luciferase (Luc2) and characterized for MSC consensus markers expression, differentiation, and risk of cellular transformation. A calvarial defect was created in non‐obese diabetic/severe combined immunodeficiency (NOD/SCID) mice and allografts were implanted, with or without cell coating. Bioluminescence imaging (BLI), microcomputed tomography (μCT), histology, immunofluorescence, and biomechanical tests were performed. Characterization of iNCC‐MPC‐Luc2 vs BM‐MSC‐Luc2 showed no difference in MSC markers expression and differentiation in vitro. In vivo, BLI indicated survival of both cell types for at least 8 weeks. At week 8, μCT analysis showed enhanced structural parameters in the iNCC‐MPC‐Luc2 group and increased bone volume in the BM‐MSC‐Luc2 group compared to controls. Histology demonstrated improved integration of iNCC‐MPC‐Luc2 allografts compared to BM‐MSC‐Luc2 group and controls. Human osteocalcin and collagen type 1 were detected at the allograft‐host interphase in cell‐seeded groups. The iNCC‐MPC‐Luc2 group also demonstrated improved biomechanical properties compared to BM‐MSC‐Luc2 implants and cell‐free controls. Our results show an improved integration of iNCC‐MPC‐Luc2‐coated allografts compared to BM‐MSC‐Luc2 and controls, suggesting the use of iNCC‐MPCs as potential cell source for cranial bone repair. John Wiley & Sons, Inc. 2021-01-29 /pmc/articles/PMC8046069/ /pubmed/33512772 http://dx.doi.org/10.1002/sctm.20-0364 Text en © 2020 The Authors. stem cells translational medicine published by Wiley Periodicals LLC on behalf of AlphaMed Press https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Tissue‐specific Progenitor and Stem Cells Glaeser, Juliane D. Behrens, Phillip Stefanovic, Tina Salehi, Khosrowdad Papalamprou, Angela Tawackoli, Wafa Metzger, Melodie F. Eberlein, Samuel Nelson, Trevor Arabi, Yasaman Kim, Kevin Baloh, Robert H. Ben‐David, Shiran Cohn‐Schwartz, Doron Ryu, Robert Bae, Hyun W. Gazit, Zulma Sheyn, Dmitriy Neural crest‐derived mesenchymal progenitor cells enhance cranial allograft integration |
title | Neural crest‐derived mesenchymal progenitor cells enhance cranial allograft integration |
title_full | Neural crest‐derived mesenchymal progenitor cells enhance cranial allograft integration |
title_fullStr | Neural crest‐derived mesenchymal progenitor cells enhance cranial allograft integration |
title_full_unstemmed | Neural crest‐derived mesenchymal progenitor cells enhance cranial allograft integration |
title_short | Neural crest‐derived mesenchymal progenitor cells enhance cranial allograft integration |
title_sort | neural crest‐derived mesenchymal progenitor cells enhance cranial allograft integration |
topic | Tissue‐specific Progenitor and Stem Cells |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046069/ https://www.ncbi.nlm.nih.gov/pubmed/33512772 http://dx.doi.org/10.1002/sctm.20-0364 |
work_keys_str_mv | AT glaeserjulianed neuralcrestderivedmesenchymalprogenitorcellsenhancecranialallograftintegration AT behrensphillip neuralcrestderivedmesenchymalprogenitorcellsenhancecranialallograftintegration AT stefanovictina neuralcrestderivedmesenchymalprogenitorcellsenhancecranialallograftintegration AT salehikhosrowdad neuralcrestderivedmesenchymalprogenitorcellsenhancecranialallograftintegration AT papalamprouangela neuralcrestderivedmesenchymalprogenitorcellsenhancecranialallograftintegration AT tawackoliwafa neuralcrestderivedmesenchymalprogenitorcellsenhancecranialallograftintegration AT metzgermelodief neuralcrestderivedmesenchymalprogenitorcellsenhancecranialallograftintegration AT eberleinsamuel neuralcrestderivedmesenchymalprogenitorcellsenhancecranialallograftintegration AT nelsontrevor neuralcrestderivedmesenchymalprogenitorcellsenhancecranialallograftintegration AT arabiyasaman neuralcrestderivedmesenchymalprogenitorcellsenhancecranialallograftintegration AT kimkevin neuralcrestderivedmesenchymalprogenitorcellsenhancecranialallograftintegration AT balohroberth neuralcrestderivedmesenchymalprogenitorcellsenhancecranialallograftintegration AT bendavidshiran neuralcrestderivedmesenchymalprogenitorcellsenhancecranialallograftintegration AT cohnschwartzdoron neuralcrestderivedmesenchymalprogenitorcellsenhancecranialallograftintegration AT ryurobert neuralcrestderivedmesenchymalprogenitorcellsenhancecranialallograftintegration AT baehyunw neuralcrestderivedmesenchymalprogenitorcellsenhancecranialallograftintegration AT gazitzulma neuralcrestderivedmesenchymalprogenitorcellsenhancecranialallograftintegration AT sheyndmitriy neuralcrestderivedmesenchymalprogenitorcellsenhancecranialallograftintegration |